RESEARCH PAPER |
|
Year : 2017 | Volume
: 8
| Issue : 4 | Page : 166-171 |
|
Efficacy and safety of oral diclofenac sustained release versus transdermal diclofenac patch in chronic musculoskeletal pain: A randomized, open label trial
Viraj Ashok Shinde1, Mrunalini Kalikar1, Satyajeet Jagtap1, Ganesh N Dakhale1, Mangesh Bankar2, Chaitali S Bajait1, Vijay M Motghare1, Ashlesha A Pashilkar3, Latesh B Raghute1, Ajita D Khamkar1
1 Department of Pharmacology, Government Medical College, Nagpur, Maharashtra, India 2 Department of Pharmacology, Andaman and Nicobar Islands Institute of Medical Sciences, Port Blair, Andaman and Nicobar, India 3 Department of Pharmaceutics, Dadasaheb Balpande College of Pharmacy, Nagpur, Maharashtra, India
Correspondence Address:
Viraj Ashok Shinde Flat No. 15/B Wing Giridhar Parijat Hsg. Society, 525 (New) Sadashiv Peth, Pune - 411 030, Maharashtra India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/jpp.JPP_35_17
|
|
Introduction: To compare the efficacy, safety, and tolerability of transdermal patches of diclofenac sodium with oral diclofenac sustained release (SR) in patients of chronic musculoskeletal MSK pain conditions. Materials and Methods: The eligible patients were given either transdermal diclofenac patch or tablet diclofenac SR. Pain was assessed at 2 and 4 weeks using a visual analog scale. Adverse events were recorded. Patients with 18–65 years old of either gender with score of ≥4 on a 11-item numeric rating scale-numeric version of visual analog scale for pain with diagnosis of primary osteoarthritis (OA) of the knee or hand of at least 3 months duration, with independent radiological confirmation of OA or having pain associated with other MSK conditions such as soft-tissue rheumatism, cervical and lumbar back pain, and fibromyalgia, of at least 3 months duration were included in this study. Results: Transdermal diclofenac diethylamine patch and tablet diclofenac sodium sustained release (SR) do not significantly differ in the reduction of numerical rating scores at the end of 4 weeks (P = 0.8393). Conclusion: Transdermal diclofenac was equi-efficacious as tablet diclofenac sodium SR in reducing pain due to chronic MSK pain conditions.
|
|
|
|
[FULL TEXT] [PDF]* |
|
 |
|